Pulmatrix to Merge with Eos SENOLYTIX in Highly Dilutive Reverse Merger; Existing Shareholders to Own 6% of Combined Entity

summarizeSummary

Pulmatrix announced a definitive merger agreement to acquire Eos SENOLYTIX, effectively transforming Pulmatrix into Eos SENOLYTIX, Inc. Existing Pulmatrix shareholders will own approximately 6% of the combined company, while Eos stockholders will own 94%.

check_boxKey Events

• Definitive Reverse Merger Agreement

  Pulmatrix, Inc. has entered into a definitive merger agreement to acquire Eos SENOLYTIX, Inc., a biotechnology company focused on developing gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.

• Significant Ownership Shift and Dilution

  Upon closing, pre-Merger Eos stockholders, including financing investors, are expected to own approximately 94% of the combined company, while existing Pulmatrix stockholders will own approximately 6% on a fully-diluted basis.

• Concurrent Private Financings

  The merger is accompanied by definitive agreements for concurrent private financings totaling $19 million in aggregate gross proceeds. This includes a $1 million investment in Pulmatrix from RCM Eos PIPE HOLDINGS LLC via Series B Convertible Preferred Stock at a conversion price of $2.20 per share.

• Corporate Rebranding and Leadership Change

  The combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker symbol 'EOSX'. Kevin Slawin, M.D., Founder and CEO of Eos, will lead the merged entity as CEO. The board of directors is expected to consist of six members, with five designated by Eos.

auto_awesomeAnalysis

This filing announces a definitive reverse merger agreement that will fundamentally transform Pulmatrix into Eos SENOLYTIX, Inc. The most critical aspect for existing Pulmatrix shareholders is the extreme dilution, as they are expected to own only approximately 6% of the combined company, while Eos stockholders will own 94%. This represents a near-complete change of control and business focus. The transaction, occurring while Pulmatrix's stock is trading near its 52-week low, suggests a distressed situation for the legacy business, necessitating this transformative, albeit highly dilutive, capital infusion and change of control. While the $1 million investment in Pulmatrix via Series B Convertible Preferred Stock is priced at a premium ($2.20 conversion price vs. current $1.33 stock price), this is a small component of the overall $19 million financing and does not offset the massive dilution for current shareholders. Investors should be aware of the complete strategic pivot and the substantial loss of ownership.